Journals / European Journal of Therapeutics / 2020 / Cilt: 26 - Sayı: 4

Gut Microbiota: Formation, Lifelong Developmentand Relation to Cytochrome P450 System, Diseases,Drug Bioavailability and Drug Interactions

Pages
344–349
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, we aim to emphasize the importance of microbiota and drug interactions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The human microbiota is an essential and individual part of the human body composed of microorganisms that live in symbiosis with the human body.
📊
Key Findings & Data:It is formed prenatally and changes throughout a person’s life due to endogenous and exogenous factors such as birth, geography, gender, sex hormones, genetics, mode of birth, age, lifestyle, nutrition, use of antibiotics, and disease-related changes.
💡
Conclusion & Impact:In this review, we aim to emphasize the importance of microbiota and drug interactions.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The human microbiota is an essential and individual part of the human body composed of microorganisms that live in symbiosis with the human body. It is formed prenatally and changes throughout a person’s life due to endogenous and exogenous factors such as birth, geography, gender, sex hormones, genetics, mode of birth, age, lifestyle, nutrition, use of antibiotics, and disease-related changes. Studies on the microbiota have mostly focused on its relation to diseases, but the gut microbiota is also very sensitive to xenobiotics, which directy or indirectly alter the pharmacokinetics of drugs used by the host. Although the gut microbiota recovers in a few weeks, some changes may be permanent. It is important to consider changes in drug bioavailability in patients who were recently or currently treated with antibiotics for the safe and efficient pharmacotherapy of patients. With advanced knowledge about the microbiota and advances in the field of microbiome genetics, it may be possible that in the future, a person’s microbiota map is used in personalizing drug treatment. In this review, we aim to emphasize the importance of microbiota and drug interactions.

🔖

Cite This Article

DORA, D. D., CESUR, B. (2022). Gut Microbiota: Formation, Lifelong Developmentand Relation to Cytochrome P450 System, Diseases,Drug Bioavailability and Drug Interactions. European Journal of Therapeutics, Cilt: 26 - Sayı: 4, 344–349. https://ajindex.com/articles/512204

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol 2016
  2. e1002533. [Crossref] 2. Altuntas Y, Batman A. Mikrobiyota ve metabolik sendrom. Turk Kardiyol Dern Ars 2017
  3. [Crossref] 3. Kootte RS, Vrieze A, Holleman F, Dallinga-Thie GM, Zoetendal EG, de Vos WM, et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab 2012
  4. [Crossref] 4. Biesalski HK. Nutrition meets the microbiome: micronutrients and the microbiota. Ann N Y Acad Sci 2016
  5. [Crossref] 5. Lebeer S, Spacova I. Exploring human host-microbiome interactions in health and disease-how to not get lost in translation. Genome Biol 2019
  6. [Crossref] 6. Hasan N, Yang H. Factors affecting the composition of the gut microbiota, and its modulation. PeerJ 2019
  7. e7502. [Crossref] 7. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. Science 2012
  8. [Crossref] 8. Moore RE, Townsend SD. Temporal development of the infant gut microbiome. Open Biol 2019
  9. 190128. [Crossref] 9. Peterson J, Garges S, Giovanni M, Mcinnes P, Wang L, Schloss JA, et al. The NIH human microbiome project. Genome Res 2009
  10. [Crossref] 10. Cusack S, Paul WO. Challenges and implications for biomedical research and intervention studies in older populations: Insights from the ELDERMET study. Gerontology 2013
  11. [Crossref] 11. Claesson MJ, Jeffery IB, Conde S, Power SE. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012
  12. [Crossref] 12. Lynch DB, Jeffery IB, Cusack S, O’Connor EM, O’Toole PW. Diet-microbiota-health interactions in older subjects: implications for healthy aging. In Aging and Health-A Systems Biology Perspective. Interdiscip Top Gerontol 2015
  13. [Crossref] 13. Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J 2017
  14. [Crossref] 14. Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol 2017
  15. [Crossref] 15. Wang Y, Wang B, Wu J, Jiang X, Tang H, Nielsen OH. Modulation of gut microbiota in pathological states. Engineering 2017
  16. [Crossref] 16. Walker RW, Clemente JC, Peter I, Loos RJ. The prenatal gut microbiome: are we colonized with bacteria i